Univariate survival analysis in sibling and unrelated donor groups
| Sibling donors (n = 32) . | Unrelated donors (n = 34) . | |||||
|---|---|---|---|---|---|---|
| n . | 2-y survival . | Log-rank P . | n . | 2-y survival . | Log-rank P . | |
| Current diagnosis | ||||||
| PMF | 14 (44%) | 71% (48%, 95%) | .67 | 25 (74%) | 36% (17%, 55%) | .94 |
| ET/PV | 18 (56%) | 76% (56%, 97%) | — | 9 (26%) | 33% (3%, 64%) | — |
| Lille score | ||||||
| 0/1 | 23 (72%) | 73% (54%, 91%) | .81 | 23 (68%) | 35% (15%, 54%) | .88 |
| 2 | 9 (28%) | 78% (51%, 100%) | — | 11 (32%) | 36% (8%, 65%) | — |
| Gender | ||||||
| Female | 13 (41%) | 69% (44%, 94%) | .55 | 15 (44%) | 40% (15%, 65%) | .81 |
| Male | 19 (59%) | 78% (58%, 97%) | — | 19 (56%) | 32% (11%, 52%) | — |
| Age-adjusted DIPSS | ||||||
| Low-risk/int-1 | 18 (56%) | 71% (49%, 92%) | .67 | 19 (56%) | 42% (20%, 64%) | .14 |
| Int-2/high-risk | 11 (34%) | 82% (59%, 100%) | — | 12 (35%) | 17% (0%, 38%) | — |
| Donor HLA | ||||||
| Match | 30 (94%) | 72% (56%, 89%) | .43 | 25 (74%) | 40% (21%, 59%) | .33 |
| Mismatch | 2 (6%) | 100% | — | 9 (26%) | 22% (0%, 49%) | — |
| Baseline JAK-2 V617F | ||||||
| Positive | 12 (38%) | 76% (56%, 97%) | .68 | 18 (53%) | 28% (7%, 48%) | .29 |
| Negative | 17 (53%) | 64% (36%, 92%) | — | 16 (47%) | 44% (19%, 68%) | — |
| Sibling donors (n = 32) . | Unrelated donors (n = 34) . | |||||
|---|---|---|---|---|---|---|
| n . | 2-y survival . | Log-rank P . | n . | 2-y survival . | Log-rank P . | |
| Current diagnosis | ||||||
| PMF | 14 (44%) | 71% (48%, 95%) | .67 | 25 (74%) | 36% (17%, 55%) | .94 |
| ET/PV | 18 (56%) | 76% (56%, 97%) | — | 9 (26%) | 33% (3%, 64%) | — |
| Lille score | ||||||
| 0/1 | 23 (72%) | 73% (54%, 91%) | .81 | 23 (68%) | 35% (15%, 54%) | .88 |
| 2 | 9 (28%) | 78% (51%, 100%) | — | 11 (32%) | 36% (8%, 65%) | — |
| Gender | ||||||
| Female | 13 (41%) | 69% (44%, 94%) | .55 | 15 (44%) | 40% (15%, 65%) | .81 |
| Male | 19 (59%) | 78% (58%, 97%) | — | 19 (56%) | 32% (11%, 52%) | — |
| Age-adjusted DIPSS | ||||||
| Low-risk/int-1 | 18 (56%) | 71% (49%, 92%) | .67 | 19 (56%) | 42% (20%, 64%) | .14 |
| Int-2/high-risk | 11 (34%) | 82% (59%, 100%) | — | 12 (35%) | 17% (0%, 38%) | — |
| Donor HLA | ||||||
| Match | 30 (94%) | 72% (56%, 89%) | .43 | 25 (74%) | 40% (21%, 59%) | .33 |
| Mismatch | 2 (6%) | 100% | — | 9 (26%) | 22% (0%, 49%) | — |
| Baseline JAK-2 V617F | ||||||
| Positive | 12 (38%) | 76% (56%, 97%) | .68 | 18 (53%) | 28% (7%, 48%) | .29 |
| Negative | 17 (53%) | 64% (36%, 92%) | — | 16 (47%) | 44% (19%, 68%) | — |